Skip to main content
You have permission to edit this article.
Merck says COVID-19 pill cuts risk of death, hospitalization

Merck says COVID-19 pill cuts risk of death, hospitalization

  • Updated
  • 0
Virus Outbreak Treatment Merck

If cleared, the new drug by pharmaceutical company Merck would be the first pill shown to treat COVID-19.

WASHINGTON — In a potential leap forward in the global fight against the pandemic, drugmaker Merck said Friday that its experimental pill for people sick with COVID-19 reduced hospitalizations and deaths by half.

That could add a whole new, easy-to-use weapon to an arsenal that already includes the COVID-19 vaccine.

The company said it will soon ask health officials in the U.S. and around the world to authorize the pill’s use. A decision from the U.S. Food and Drug Administration could come within weeks after that, and the drug, if it gets the OK, could be distributed quickly soon afterward.

If cleared, it would be the first pill shown to treat COVID-19. All other therapies now authorized in the U.S. require an IV or injection. A pill taken at home, by contrast, would ease pressure on hospitals and could also help curb outbreaks in poorer and more remote corners of the world that don’t have access to the more expensive infusion therapies.

Merck and its partner Ridgeback Biotherapeutics said early results showed that patients who received the drug, molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as those who received a dummy pill.

The study tracked 775 adults with mild-to-moderate COVID-19 who were considered high risk for severe disease because of health problems such as obesity, diabetes or heart disease. The results have not been reviewed by outside experts, the usual procedure for vetting new medical research.

Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. After that time period, there were no deaths among those who received the drug, compared with eight in the placebo group, according to Merck.

The University of Nebraska Medical Center was among more than 100 sites that enrolled patients in the trial. Dr. Diana Florescu, a professor in UNMC’s internal medicine department, said the oral drug, if approved by the FDA, should help decrease hospitalizations, a plus for overwhelmed health care facilities. In addition, patients who have to wait to start monoclonal antibody infusions could start on the pill in the interim. Taking the pills does not preclude monoclonal antibody therapy.

Florescu, an infectious diseases physician with Nebraska Medicine, said UNMC also will offer another trial of the drug beginning as soon as this month. That trial will test whether the drug can prevent family members of people diagnosed with COVID-19 from becoming ill and from developing severe disease, just as Tamiflu is used to prevent people who have been exposed to influenza from becoming ill.

Even with the news of a potentially effective new coronavirus treatment, experts stressed the importance of vaccines for controlling the pandemic, given that they help prevent transmission and also reduce the severity of illness in those who do get infected.

White House coronavirus coordinator Jeff Zients said vaccination will remain the government’s main strategy for controlling the pandemic. “We want to prevent infections, not just wait to treat them when they happen,” he said.

Dr. Anthony Fauci, the government’s foremost authority on infectious diseases, called the results from Merck “very good news.”

Merck studied its drug only in people who were not vaccinated. But FDA regulators may consider authorizing it for broader use in vaccinated patients who get breakthrough COVID-19 symptoms.

Andrew Pekosz of Johns Hopkins University predicted vaccines and antiviral drugs would ultimately be used together to protect against the worst effects of COVID-19.

“These shouldn’t be seen as replacements for vaccination — the two should be seen as two strategies that can be used together to significantly reduce severe disease,” said Pekosz, a virology specialist.

Patients take four pills of molnupiravir twice a day for five days. Side effects were reported by both groups in the Merck trial, but they were slightly more common among those who received a dummy pill. The company did not specify the problems.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease. That’s not surprising, given that antiviral drugs are most effective when used before the virus ramps up in the body.

The U.S. has approved one antiviral drug, remdesivir, for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs are expensive and have to be given by IV or injection at hospitals or clinics, and supplies have been stretched by the latest surge of the delta variant.

The antibody drugs have been shown to reduce hospitalization and death by roughly 70% when given to high-risk patients, about 20 percentage points more than Merck’s pill. But experts cautioned against comparing results from the two, given the preliminary nature of Merck’s data.

Health experts, including Fauci, have long called for a convenient pill that patients could take when COVID-19 symptoms first appear.

Like other antivirals, Merck’s pill works by interfering with the virus’s ability to copy its genetic code and reproduce itself.

The U.S. government has committed to purchasing enough pills to treat 1.7 million people, assuming the FDA authorizes the drug. Merck said it can produce pills for 10 million patients by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs and could report results in the coming weeks and months.

World-Herald Staff Writer Julie Anderson contributed to this report.

Be the first to know

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Get up-to-the-minute news sent straight to your device.



Breaking News

Huskers Breaking News

News Alert